BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 17015743)

  • 1. Retrovirus-mediated over-expression of decay-accelerating factor rescues Crry-deficient erythrocytes from acute alternative pathway complement attack.
    Kim DD; Miwa T; Song WC
    J Immunol; 2006 Oct; 177(8):5558-66. PubMed ID: 17015743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement-mediated clearance of erythrocytes: mechanism and delineation of the regulatory roles of Crry and DAF. Decay-accelerating factor.
    Molina H; Miwa T; Zhou L; Hilliard B; Mastellos D; Maldonado MA; Lambris JD; Song WC
    Blood; 2002 Dec; 100(13):4544-9. PubMed ID: 12393518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deletion of Crry and DAF on murine platelets stimulates thrombopoiesis and increases factor H-dependent resistance of peripheral platelets to complement attack.
    Barata L; Miwa T; Sato S; Kim D; Mohammed I; Song WC
    J Immunol; 2013 Mar; 190(6):2886-95. PubMed ID: 23390291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement attack.
    Miwa T; Zhou L; Hilliard B; Molina H; Song WC
    Blood; 2002 May; 99(10):3707-16. PubMed ID: 11986227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein.
    Kim YU; Kinoshita T; Molina H; Hourcade D; Seya T; Wagner LM; Holers VM
    J Exp Med; 1995 Jan; 181(1):151-9. PubMed ID: 7528766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deficiency of decay-accelerating factor and complement receptor 1-related gene/protein y on murine platelets leads to complement-dependent clearance by the macrophage phagocytic receptor CRIg.
    Kim DD; Miwa T; Kimura Y; Schwendener RA; van Lookeren Campagne M; Song WC
    Blood; 2008 Aug; 112(4):1109-19. PubMed ID: 18524992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DAF/Crry double deficiency in mice exacerbates nephrotoxic serum-induced proteinuria despite markedly reduced systemic complement activity.
    Miwa T; Zhou L; Tudoran R; Lambris JD; Madaio MP; Nangaku M; Molina H; Song WC
    Mol Immunol; 2007 Jan; 44(1-3):139-46. PubMed ID: 16887189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of glycosylphosphatidylinositol-anchored decay accelerating factor (GPI-DAF) and transmembrane DAF gene expression in wild-type and GPI-DAF gene knockout mice using polyclonal and monoclonal antibodies with dual or single specificity.
    Miwa T; Sun X; Ohta R; Okada N; Harris CL; Morgan BP; Song WC
    Immunology; 2001 Oct; 104(2):207-14. PubMed ID: 11683961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mouse Crry/p65. Characterization of monoclonal antibodies and the tissue distribution of a functional homologue of human MCP and DAF.
    Li B; Sallee C; Dehoff M; Foley S; Molina H; Holers VM
    J Immunol; 1993 Oct; 151(8):4295-305. PubMed ID: 7691944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the effects of activation of the alternative pathway of complement on erythrocytes with an isolated deficiency of decay accelerating factor.
    Holguin MH; Martin CB; Bernshaw NJ; Parker CJ
    J Immunol; 1992 Jan; 148(2):498-502. PubMed ID: 1370313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting.
    Sun X; Funk CD; Deng C; Sahu A; Lambris JD; Song WC
    Proc Natl Acad Sci U S A; 1999 Jan; 96(2):628-33. PubMed ID: 9892684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rat T cells express neither CD55 nor CD59 and are dependent on Crry for protection from homologous complement.
    Hanna S; Spiller O; Linton SM; Mead RJ; Morgan B
    Eur J Immunol; 2002 Feb; 32(2):502-9. PubMed ID: 11828367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mouse Crry/p65 is a regulator of the alternative pathway of complement activation.
    Foley S; Li B; Dehoff M; Molina H; Holers VM
    Eur J Immunol; 1993 Jun; 23(6):1381-4. PubMed ID: 8500531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decay-accelerating factor induction by tumour necrosis factor-alpha, through a phosphatidylinositol-3 kinase and protein kinase C-dependent pathway, protects murine vascular endothelial cells against complement deposition.
    Ahmad SR; Lidington EA; Ohta R; Okada N; Robson MG; Davies KA; Leitges M; Harris CL; Haskard DO; Mason JC
    Immunology; 2003 Oct; 110(2):258-68. PubMed ID: 14511240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crry deficiency in complement sufficient mice: C3 consumption occurs without associated renal injury.
    Ruseva MM; Hughes TR; Donev RM; Sivasankar B; Pickering MC; Wu X; Harris CL; Morgan BP
    Mol Immunol; 2009 Feb; 46(5):803-11. PubMed ID: 18947875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The serum resistance of malaria-infected erythrocytes.
    Kawamoto Y; Kojima K; Hitsumoto Y; Okada H; Holers VM; Miyama A
    Immunology; 1997 May; 91(1):7-12. PubMed ID: 9203959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of a hybrid complement regulatory protein, membrane cofactor protein decay accelerating factor on Chinese hamster ovary. Comparison of its regulatory effect with those of decay accelerating factor and membrane cofactor protein.
    Iwata K; Seya T; Ariga H; Nagasawa S
    J Immunol; 1994 Apr; 152(7):3436-44. PubMed ID: 7511647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutting edge: treatment of complement regulatory protein deficiency by retroviral in vivo gene therapy.
    Spitzer D; Wu X; Ma X; Xu L; Ponder KP; Atkinson JP
    J Immunol; 2006 Oct; 177(8):4953-6. PubMed ID: 17015675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Test for ability of decay-accelerating factor (DAF, CD55) and CD59 to alleviate complement-mediated damage of xeno-erythrocytes.
    Miyagawa S; Shirakura R; Matsumiya G; Nakata S; Matsuda H; Hatanaka M; Matsumoto M; Kitamura H; Seya T
    Scand J Immunol; 1993 Jul; 38(1):37-44. PubMed ID: 7687071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis.
    Sogabe H; Nangaku M; Ishibashi Y; Wada T; Fujita T; Sun X; Miwa T; Madaio MP; Song WC
    J Immunol; 2001 Sep; 167(5):2791-7. PubMed ID: 11509624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.